| Literature DB >> 35625434 |
Maria Florencia Lezcano1,2,3, Giannina Álvarez1,2, Priscila Chuhuaicura2,4, Karina Godoy5, Josefa Alarcón1, Francisca Acevedo6,7, Iván Gareis3, Fernando José Dias2,4.
Abstract
In the last two decades, artificial scaffolds for nerve regeneration have been produced using a variety of polymers. Polyhydroxybutyrate (PHB) is a natural polyester that can be easily processed and offer several advantages; hence, the purpose of this review is to provide a better understanding of the efficacy of therapeutic approaches involving PHB scaffolds in promoting peripheral nerve regeneration following nerve dissection in animal models. A systematic literature review was performed following the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA) criteria. The revised databases were: Pub-Med/MEDLINE, Web of Science, Science Direct, EMBASE, and SCOPUS. Sixteen studies were included in this review. Different animal models and nerves were studied. Extension of nerve gaps reconnected by PHB scaffolds and the time periods of analysis were varied. The additives included in the scaffolds, if any, were growth factors, neurotrophins, other biopolymers, and neural progenitor cells. The analysis of the quality of the studies revealed good quality in general, with some aspects that could be improved. The analysis of the risk of bias revealed several weaknesses in all studies. The use of PHB as a biomaterial to prepare tubular scaffolds for nerve regeneration was shown to be promising. The incorporation of additives appears to be a trend that improves nerve regeneration. One of the main weaknesses of the reviewed articles was the lack of standardized experimentation on animals. It is recommended to follow the currently available guidelines to improve the design, avoid the risk of bias, maximize the quality of studies, and enhance translationality.Entities:
Keywords: PHA—polyhydroxyalkanoate; biomaterial; neural repair; peripheral nervous system—PNS
Year: 2022 PMID: 35625434 PMCID: PMC9138984 DOI: 10.3390/biology11050706
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737
Figure 1General chemical structure of the PHAs. Typical values: x = 1 to 4; n = 1000 to 10,000; R = alkyl group (CmH2m+1) or functionalized alkyl group. Reused from [37] with kind permission of John Wiley and Sons.
Figure 2Chemical structure of PHAs under medical investigation. Reused from [37] with kind permission of John Wiley and Sons.
Figure 3Systematic search flow diagram.
Evidence extracted from animal studies selected.
| Authors and Year of Publication | Nerve (Type)/Gap Size/Time Periods | Animal ( | PHB Formula Used | Scaffold Fabrication Method | Additive | Methods Used | Conclusion or Main Outcome |
|---|---|---|---|---|---|---|---|
| Borkenhagen et al., 1998 [ | Sciatic nerve (mixed)/8 mm/4, 12, 24 weeks | Rats (26) | Poly[glycolide-co-(ε-caprolactone)]-diol & poly[(R)-3-hydroxybutyric acid-co-(R)-3-hydroxyvaleric acid]-diol | Melt extrusion (tube) | No additive | Macroscopic morphology, histology | PHB holds promises for its utilization as nerve guidance channels. |
| Ljungberg et al., 1999 [ | Superficial radial nerve (sensory)/~2–3 mm/6, 12 months | Cats (20) | Polyhydroxybutyrate (PHB) | Rolled sheets (tube) and fibrin glue. | No additive | Histology, quantitative immunohistochem. (IHC) | No differences between wrapping the nerve ends in PHB sheet or epineurally suturing of the nerve. |
| Hazari et al., 1999a [ | Radial Nerve (mixed)/2–3 mm/6, 12 months | Cats (20) | Poly-3-hydroxbutyrate (PHB) | Rolled PHB sheet wrapped around the nerve ends & Tissue Glue | No additive | Histology, quantitative IHC | No differences beetwen PHB tube and Epineural Repair |
| Hazari et al., 1999b [ | Sciatic nerve (mixed)/10 mm/7, 14, 30 days | Rats (36) | Poly-3-hydroxybutyrate | Rolled sheets sealed longitudinallywith cyanoacrylate (tube) | No additive | Quantitative IHC, morphometry | Good nerve regeneration in comparison with nerve grafts. |
| Young et al., 2002 [ | Common peroneal nerve (Mixed)/2, 3, 4 cm/2, 3, 6, 9 weeks | Rabbit (90) | Poly-3-hydroxybutyrate (PHB) | Sterile PHB sheets with unidirectional fiber orientation (long axes) | No additive | IHC, histology, macroscopic morphology | PHB conduits support peripheral nerve regeneration up to 63 days. They are suitable for long-gap nerve injury repair. |
| Mohanna et al., 2003 [ | Common peroneal nerve (Mixed)/2, 4 cm/3, 6, 9 weeks | Rabbit (90) | Poly 3-hydroxybutyrate (PHB) | Rolled PHB sheet around (16 G) cannula, long axes fiber orientation | Glial growth factor (rhGGF2, 1.29 mg mL−1, 80 kDa) diluted in 1 mL of 50:50 alginate fibronectin solution | Quantitative IHC | Inhibition of regeneration of nerve regeneration was partially reversed by the addition of GGF to the PHB conduits. PHB-GGF stimulates a progressive and sustainable regeneration increase in long nerve gap conduits. |
| Hart et al., 2003 [ | Sciatic nerve (mixed)/10 mm/2, 4 months | Rats (30) | Poly-3-hydroxybutyrate (PHB) | Rolled sheets (tube) | Leukemia inhibitory factor (recombinant murine rhLIF 100 ng/mL) hosted in a matrix of hydrogel comprising 2% ultra-pure low-molecular-weight high-mannuronic-acid-content calcium alginate and 0.05% bovine fibronectin | Quantitative IHC, macro morphometry | rhLIF has a potential role in promoting peripheral nerve regeneration after secondary repair and can be effectively delivered within PHB conduits for nerve repair. |
| Birchall et al., 2004 [ | Recurrent laryngeal nerve (mixed)/4 mm/30, 60, 120 days | Minipig (6) | Polyhydroxybutyrate (PHB) | PHB sheet rolled to form a conduit | No additive | IHC; morphometry; histologic quantif.; macroscopic morphology | Functional and histological recovery within 2–4 months and appears to sustain abductor muscle fiber morphology. Recovery occurs despite a complex inflammatory response. |
| Mohanna et al., 2005 [ | Peroneal (mixed)/20, 40 mm/120 days | Rabbit (30) | Poly-3-hydroxybutyrate (PHB) | Rolled sheets (tube) | Glial growth factor (rthGGF2, 1.29 mg mL−1, 80 kDa) diluted in 1 mL of 50:50 alginate fibronectin solution | Histology, quant. IHC, ultrastructure (TEM), muscle atrophy | GGF-containing PHB conduits promoted sustained axonal regeneration and improved target muscle reinnervation. |
| Kalbermatten et al., 2008a [ | Sciatic (mixed)/10 mm/2 weeks | Rats (24) | Poly-3-hydroxybutyrate (PHB) | PHB sheets rolled (16 G) 14 mm long, 2 mm diameter | A fibrinogen-cell solution was made in 1:10 dilution from Tisseel® containing 9 mg/mL fibrinogen and 80 × 106 Schwann cells/mL. This solution (25 mL) was used to coat PHB that was treated with 25 mL of diluted thrombin solution (5 IU/mL) for 10 min. | Histology, IHC, macroscopic morphology | Beneficial combinatory effect of an optimized matrix, cells and conduit material (PHB) as a step towards bridging nerve gaps. |
| Kalbermatten et al., 2008b [ | Sciatic (mixed)/10 mm/2 weeks | Rats | Poly-3-hydroxybutyrate (PHB) | Rolled sheets of compressed PHB fibers soaked in fibrin glue (tube) | About 80 × 106 Schwann cells/mL were suspended in 25 mL of fibrinogen solution. PHB conduits were coated with 25 mL of a diluted thrombin (5 IU/mL) solution for 10 min and then the fibrinogen/cell solution was added. | Histology, IHC, macroscopic morphology | PHB showed significant advantage in rapidly connecting a nerve gap lesion. |
| Kalbermatten et al., 2008c [ | Sciatic (mixed)/10 mm/2, 4 weeks | Rodents | Poly-3-hydroxybutyrate (PHB) | PHB sheets wrapped around a cannula and heat sealed (tube) vs. Fibrin conduits. | No additive | Quantitative IHC, morphology | Advantage of the new fibrin conduit for the important initial phase of peripheral nerve regeneration in comparison with PHB conduit. |
| Bian et al., 2009 [ | Sciatic (mixed)/10 mm/1, 2, 3 months | Rats (60) | Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx) | Dipping–leaching | No additive | Electrophysiol. analysis, histology, ultrastructure (TEM) | PHBHHx nerve conduits showed proper mechanical strengths and biodegradability artificial nerve conduits to repair nerve damages. |
| Durgam et al., 2010 [ | Sciatic (mixed)/10 mm/8 weeks | Rats (11) | Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB-HV) | Rolled sheets of PCL and PECA glued with a PHB-HV solution (tube) | Co-polymers of polypyrrole (PPy) with poly (ε-caprolactone) (PCL) and poly (ethyl cyanoacrylate) (PECA). Melt-pressed PHB-HV films were airbrushed with a PPy co-polymer (PPy–PCL or PPy–PECA) and pressed. | Histology | Biomaterials (PCL, PECA and PHB-HV) have good biocompatibility and support proliferation and growth neurons in vivo (without electrical stimulation). |
| Schaakxs et al., 2017 [ | Sciatic (mixed)/10 mm/12 weeks | Rats (15) | Poly-3-hydroxybutyrate (PHB) | Rolled sheets of compressed PHB fibers soaked in fibrin glue (tube) | Primary Schwann cells (SCs) isolated from adult rat sciatic nerves or SC-like differentiated adipose-derived stem cells (dASCs) from rats were trypsinised and 80 × 106 cells/mL were suspended in 25 μL diluted fibrinogen solution. The PHB strips were coated with 25 μL diluted thrombin (5 IU/mL) solution for 10 min and then the cell solution was added. | Functional gait test EMG, morphometry | The PHB strip seeded with cells provides a beneficial environment for nerve regeneration. |
| Ozer et al., 2018 [ | Sciatic (mixed)/10 mm/8 weeks | Rats (30) | Poly-3-hydroxybutyrate (PHB) | PHB (5 wt%) in chloroform by electrospinning method | Chitosan-coated PHB conduits were seeded with mesenchymal stem cells harvested from human iliac bone marrow (hMSC-bm) | Functional gait test, EMG, histology | PHB/chitosan-hMSC-bm nerve conduits may be a useful artificial guide for nerve regeneration. |
Figure 4Unidirectional fiber orientated sheet of PHB (8 × 14 mm) rolled around a 16 G cannula to form a tube 14 mm long and with an internal diameter of 1.6 mm. Reused from (Hazari et al., 1999b) [16] with kind permission of Elsevier.
Figure 5Superficial radial nerve of a cat sectioned and wrapped in a PHB conduit sealed by fibrin glue. Magnification 6×. Reused from (Ljungberg et al., 1999) [14] with kind permission of John Wiley and Sons.
Quality analysis of animal studies using ARRIVE guidelines [41] adapted for nerve regeneration treated with PHB scaffolds.
| Study | Ethics | Control | Control 2 | PHB Type | PHB Origin | Scaffold Fabric. Method | Nerve Gap Size | Nerve Studied | Period Evaluated | Surgical Procedure | Euthanasia Method | Species | Sex/Weight | Group Size & Distribution | Group Size Just. | Statistics | Complete Results | Precision Measures | Limitations | Conclusion > Objectives |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Borkenhagen et al., 1998 [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||||||
| Ljungberg et al., 1999 [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||
| Hazari et al., 1999a [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||||
| Hazari et al., 1999b [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||||||
| Young et al., 2002 [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ||||||
| Mohanna et al., 2003 [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||
| Hart et al., 2003 [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||||
| Birchall et al., 2004 [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ||||||
| Mohanna et al., 2005 [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ||||||
| Kalbermatten et al., 2008a [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ||||||
| Kalbermatten et al., 2008b [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ||||||
| Kalbermatten et al., 2008c [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||||||
| Bian et al., 2009 [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||||
| Durgam et al., 2010 [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | |||||||
| Schaakxs et al., 2017 [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ||||
| Ozer et al., 2018 [ | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● |
● = Ethics: Declares to follow ethical guidelines for animal experimentation or approval by a Scientific Ethical Committee; Control: Experimental protocol has a control group; Control 2: Experimental protocol has 2 control groups; PHB type: declares the type of the PHB used; PHB origin: declares the origin of the PHB used; scaffold fabric method: explains the fabrication method for the scaffold; nerve gap size: declares the size of the nervous GAP; nerve studied: declares nerve studied; periods evaluated: declares the time in which the evaluations were carried out; surgical procedure: explains the surgical procedures performed; euthanasia method: explains the euthanasia method used; species: declares the animal species studied; sex/weight: declares sex and weight of animals at the beginning of the experimental protocol; group size and distribution: declares the size of the experimental group and explains the distribution of animals in the groups; group size just.: justifies the sample size; statistics: declares the statistical methods used for data analysis; complete results: presents complete results of the proposed the methodology; precision measures: reveals the precision values of the quantitative data (e.g., SD; SEM or IQ distance); limitations: states the limitations of the study; conclusion > objectives: conclusion consistent with the proposed objectives.
Analysis of the risk of bias in animal studies using the SYRCLE RoB tool [42] scale adapted for nerve damage and treated with PHB scaffolds.
| STUDY | Selection Bias | Performance Bias | Detection Bias | Attrition Bias | Reporting Bias | Other | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sequence | Baseline | Allocation | Random Housing | Housing Blinding | Random Outcome Asses. | Outcome Asses. Blinding | Incomplete Outcome Addr. | Sel. Outcome Rep. | Free of Other Problems | |
| Borkenhagen et al., 1998 [ | U | U | U | U | U | U | U | U | Y | N |
| Ljungberg et al., 1999 [ | U | Y | N | U | U | U | U | Y | Y | N |
| Hazari et al., 1999a [ | U | Y | U | U | U | U | U | U | U | N |
| Hazari et al., 1999b [ | U | U | U | U | U | U | U | U | U | N |
| Young et al., 2002 [ | U | U | U | U | U | U | U | U | U | Y |
| Mohanna et al., 2003 [ | U | Y | U | U | U | U | U | U* | Y | Y |
| Hart et al., 2003 [ | U | U | U | U | U | U | U | U* | U | N |
| Birchall et al., 2004 [ | U | Y | U | U | U | U | U | U* | Y | Y |
| Mohanna et al., 2005 [ | U | Y | U | U | U | U | U | U* | Y | N |
| Kalbermatten et al., 2008a [ | U | U | U | U | U | U | U | U | U | N |
| Kalbermatten et al., 2008b [ | U | U | U | U | U | U | U | Y | Y | Y |
| Kalbermatten et al., 2008c [ | U | U | U | U | U | U | U | Y | U | Y |
| Bian et al., 2009 [ | U | U | U | U | U | U | U | U | U | Y |
| Durgam et al., 2010 [ | U | Y | U | U | U | U | U | U | Y | Y |
| Schaakxs et al., 2017 [ | U | U | U | U | U | U | U | U* | Y | Y |
| Ozer et al., 2018 [ | U* | Y | U | U | U | U | U | Y | Y | Y |
| Y = There are explanations of the assignment | Y = reports sex, weight and species | Y = There are explanations of allocation concealment | Y = There are explanations of how the accommodation was hidden | Y = There are explanations of blinding of caregivers and/or researchers | Y = There are explanations of blinded analysis of animals | Y = Informs blinded evaluation of results | Y = Animal losses explained or states no animal losses. | Y = Reports positive and negative results | Y = Nothing unsual (bias) | |
| U = No explanation of the assignment. | U = Lack of baseline data | U = No explanation of allocation concealment | U = No explanation of accommodation concealment | U = No explanations of blinding of caregivers and/or researchers | U = No explanations of blinded analysis of animals | U = No information from blinded evaluation of the results. | U = Animal losses not declared. | U = Does not report negative results | ||